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Background
Phosphatidylinositol-3-kinase delta (PI3Kδ) mediates B-cell receptor signaling and 
microenvironmental support signals that promote the growth and survival of ma-
lignant B lymphocytes. In a phase 1 study, idelalisib, an orally active selective PI3Kδ 
inhibitor, showed antitumor activity in patients with previously treated indolent 
non-Hodgkin’s lymphomas.
Methods
In this single-group, open-label, phase 2 study, 125 patients with indolent non-Hodg-
kin’s lymphomas who had not had a response to rituximab and an alkylating agent or 
had had a relapse within 6 months after receipt of those therapies were administered 
idelalisib, 150 mg twice daily, until the disease progressed or the patient withdrew 
from the study. The primary end point was the overall rate of response; secondary end 
points included the duration of response, progression-free survival, and safety.
Results
The median age of the patients was 64 years (range, 33 to 87); patients had received 
a median of four prior therapies (range, 2 to 12). Subtypes of indolent non-Hodgkin’s 
lymphoma included follicular lymphoma (72 patients), small lymphocytic lymphoma 
(28), marginal-zone lymphoma (15), and lymphoplasmacytic lymphoma with or with-
out Waldenström’s macroglobulinemia (10). The response rate was 57% (71 of 125 
patients), with 6% meeting the criteria for a complete response. The median time to 
a response was 1.9 months, the median duration of response was 12.5 months, and 
the median progression-free survival was 11 months. Similar response rates were 
observed across all subtypes of indolent non-Hodgkin’s lymphoma, though the num-
bers were small for some categories. The most common adverse events of grade 3 or 
higher were neutropenia (in 27% of the patients), elevations in aminotransferase 
levels (in 13%), diarrhea (in 13%), and pneumonia (in 7%).
Conclusions
In this single-group study, idelalisib showed antitumor activity with an acceptable 
safety profile in patients with indolent non-Hodgkin’s lymphoma who had received 
extensive prior treatment. (Funded by Gilead Sciences and others; ClinicalTrials.gov 
number, NCT01282424.)
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Indolent non-Hodgkin’s lymphomas constitute approximately one third of all cases of non-Hodgkin’s lymphoma and include fol-
licular lymphoma, small lymphocytic lymphoma, 
marginal-zone lymphoma, and lymphoplasmacytic 
lymphoma with or without Waldenström’s mac-
roglobulinemia.1-3 It was estimated that approxi-
mately 20,000 people in the United States were 
diagnosed with indolent non-Hodgkin’s lympho-
ma in 2012 and that approximately 7000 died of 
this disease.4,5
The mainstay of treatment for indolent non-
Hodgkin’s lymphoma is an anti-CD20 antibody 
(primarily rituximab) in combination with chemo-
therapy consisting of alkylating agents, anthra-
cyclines, antimitotic agents, or purine analogues. 
Although the current treatments for indolent non-
Hodgkin’s lymphomas are initially effective in in-
ducing responses in most patients, they are not 
curative and show decreasing efficacy with re-
peated administrations. In addition, chemotherapy-
based regimens are associated with long-term 
toxic effects, including cumulative myelosuppres-
sion, neuropathy, cardiac toxicity, and secondary 
cancers.6-9
The most recent chemotherapeutic agent that 
has been approved by the Food and Drug Ad-
ministration for use in patients with rituximab- 
refractory indolent non-Hodgkin’s lymphoma is 
the alkylating agent bendamustine,10 which has 
become an important therapeutic option, although 
it is not curative. Radioimmunotherapies,11 such 
as iodine-131 (131I)–labeled tositumomab12 and 
yttrium-90 (90Y)–labeled ibritumomab,13 can be 
active, but owing to the potential for hemato-
logic toxic effects, their use has been limited to 
patients with adequate marrow function and lim-
ited marrow involvement by tumor. The use of 
these agents is further constrained by the complex 
procedures for their administration. For these 
reasons, 90Y-ibritumomab is used infrequently, 
and 131I-tositumomab has been withdrawn from 
the market.14 There is an unmet need for new 
treatments with novel mechanisms of action to 
offer therapeutic options for patients with ritux-
imab- and chemotherapy-refractory disease.
Phosphatidylinositol 3-kinase (PI3K) is a lipid 
kinase that has a catalytic subunit with four dif-
ferent isoforms: α, β, γ, and δ. Activation of PI3K 
generates phospholipid second messengers at 
the cell membrane that recruit and activate mul-
tiple intracellular enzymes that are regulators of 
cell proliferation, survival, and motility.15,16 The 
α and β isoforms are widely expressed in many 
tissues, whereas the γ and δ isoforms are highly 
restricted to hematopoietic cells. In B lymphocytes, 
the δ isoform (PI3Kδ) plays a central role in nor-
mal B-cell development and function, transducing 
signals from the B-cell receptor as well as from 
receptors for various cytokines, chemokines, and 
integrins.17,18 PI3Kδ signaling pathways are fre-
quently hyperactive in B-cell cancers,19-21 making 
inhibition of PI3Kδ a promising target for the 
therapy of indolent non-Hodgkin’s lymphoma.
Idelalisib is a potent, small-molecule inhibitor 
of PI3Kδ that is highly selective for the δ isoform, 
as compared with the α, β, and γ isoforms.19 In 
lymphoid cell lines and primary samples from 
patients, idelalisib blocked PI3Kδ-AKT signaling 
and promoted apoptosis.19-21 Phase 1 studies in-
volving patients with hematologic cancers showed 
that idelalisib had an acceptable safety profile 
and promising antitumor activity in patients with 
indolent non-Hodgkin’s lymphoma22 and chronic 
lymphocytic leukemia23 and established an ide-
lalisib dose.
On the basis of these data, we hypothesized 
that continuous treatment with idelalisib could 
yield clinical benefit in patients with relapsed 
indolent non-Hodgkin’s lymphoma. Our objectives 
in this multicenter, phase 2, interventional, sin-
gle-group study were to characterize the clinical 
activity and safety of the drug in a group of pa-
tients with indolent non-Hodgkin’s lymphomas 
who had received previous treatment with ritux-
imab and an alkylating agent.
Me thods
Patients
Eligible patients had a confirmed diagnosis of 
B-cell indolent non-Hodgkin’s lymphoma without 
evidence of histologic transformation, according 
to the criteria in the World Health Organization 
2008 classification. Histologic types included 
follicular lymphoma grade 1, 2, or 3a; small lym-
phocytic lymphoma; splenic, nodal, or extrano-
dal marginal-zone lymphoma; or lymphoplasma-
cytic lymphoma with or without Waldenström’s 
macroglobulinemia.3 In addition, eligible patients 
had radiographically measurable disease (defined 
as the presence of ≥1 lymph nodes with perpen-
dicular dimensions measuring ≥2.0 × ≥1.0 cm) 
and had received at least two prior systemic ther-
apies for indolent non-Hodgkin’s lymphoma. Eli-
gible patients met the criteria for refractoriness to 
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both rituximab and an alkylating agent, whether 
administered together or in successive treatment 
regimens. Refractoriness was defined per proto-
col as less than a partial response or progression 
of disease within 6 months after completion of a 
prior therapy. Other major eligibility criteria in-
cluded an age of at least 18 years, a Karnofsky 
performance score24 of 60 or higher (on a scale 
from 0 to 100, with 0 indicating death, 100 indi-
cating the complete absence of symptoms, and 
lower numbers indicating greater tumor-related 
disability), the absence of active central nervous 
system lymphoma, no prior history of hepatic 
dysfunction, no active systemic infections (hu-
man immunodeficiency virus, hepatitis B virus, 
or hepatitis C virus), and an absolute neutrophil 
count of 1.0×109 per liter or higher and a platelet 
count of 50×109 per liter or higher.
Study Design
We conducted Study 101-09 (also known as DELTA), 
a single-group, open-label, phase 2 study, at 41 
sites in the United States and Europe. Patients 
with previously treated indolent non-Hodgkin’s 
lymphoma that was refractory (as defined above) 
to both rituximab and chemotherapy that includ-
ed an alkylating agent received idelalisib, admin-
istered orally at a dose of 150 mg twice daily, 
until the disease progressed, unacceptable toxic 
effects developed, or the patient died. All patients 
provided written informed consent.
Study Oversight
The main sponsor of the study was Gilead Sciences. 
All the authors and the sponsors were responsi-
ble for designing the study protocol, amend-
ments, and analysis plan. The authors, collabora-







Male sex — no. (%) 80 (64)
Subtype of indolent non-Hodgkin’s lymphoma — no. (%)
Follicular lymphoma 72 (58)
Small lymphocytic lymphoma 28 (22)
Marginal-zone lymphoma 15 (12)
Lymphoplasmacytic lymphoma with or without Walden ström’s macroglobulinemia 10 (8)
Disease status — no. (%)
Stage III or IV 111 (89)
Elevated LDH 38 (30)
Bulky disease† 33 (26)




No. of prior regimens
Median 4
Range 2–12
Prior therapy — no. (%)
Rituximab 125 (100)
Alkylating agent 125 (100)
Combination of rituximab and alkylating agent 114 (91)
Bendamustine 81 (65)
Anthracycline 79 (63)
Purine analogue 42 (34)
Stem-cell transplantation 14 (11)
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tors, and their research teams collected all the 
data, and the sponsors confirmed the accuracy of 
the data and compiled the data for summation 
and analysis. The first draft of the manuscript 
was written by the first (academic) author and by 
an author who is employed by Gilead Sciences. 
All the authors had full access to the data and 
analyses for compilation of this report, reviewed 
and edited the manuscript, vouch for the com-
pleteness and accuracy of the data and analysis 
and for adherence of this report to the study pro-
tocol, and made the decision to submit the man-
uscript for publication. An institutional review 
board or independent ethics committee at each 
participating site approved the protocol (avail-
able with the full text of this article at NEJM.org). 
The study was conducted according to principles 
of the Declaration of Helsinki and the Interna-
tional Conference on Harmonization Guidelines 
for Good Clinical Practice.
Assessments
The primary end point was the overall rate of 
response, with complete response and partial re-
sponse assessed with the use of standard criteria 
for lymphoma25 and for Waldenström’s macro-
globulinemia.26 Responses were assessed by an 
independent review committee. Patients with in-
adequate data for an assessment of response were 
considered in the analysis of response rate as not 
having had a response to treatment. Secondary 
efficacy end points included the time to a response, 
the duration of a response (measured from the 
onset of response to disease progression), pro-
gression-free survival, and overall survival.





Prior therapy to which the disease was refractory — no./total no. (%)
Rituximab 125/125 (100)
Alkylating agent 124/125 (99)§





Disease refractory to ≥2 regimens 99/125 (79)
Disease refractory to most recent regimen 112/125 (90)
Duration of idelalisib therapy — mo
Median 6.6
Range 0.6–23.9
Treatment disposition — no. (%)
Ongoing 40 (32)
Discontinued 85 (68)
Progressive disease 41 (33)
Adverse event 25 (20)
Death 8 (6)
Investigator request 7 (6)
Withdrew consent 4 (3)
* LDH denotes lactate dehydrogenase, R-CHOP rituximab–cyclophosphamide–doxorubicin–prednisone, and R-CVP ritux-
imab–cyclophosphamide–prednisone.
† Bulky disease was defined as the presence of one or more nodes with at least one dimension of 7 cm or more.
‡ Neutropenia was defined as an absolute neutrophil count of less than 1500 per cubic millimeter, anemia as a hemo-
globin level of less than 10 g per deciliter, and thrombocytopenia as a platelet count of less than 75,000 per cubic  
millimeter.
§ Refractoriness to two cycles was required to meet the criteria for alkylator-refractory disease. One patient received only 
one cycle of chemotherapy, with no response after that cycle.
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that occurred during treatment were defined as 
those that began or worsened in the period from 
administration of the first dose of the study drug 
to 30 days after administration of the last dose. 
Events and abnormalities were graded according 
to the Common Terminology Criteria for Adverse 
Events, version 4.03.27
Patients were clinically evaluated at 2-week 
intervals during the first 12 weeks of treatment, 
at 4-week intervals from week 12 to week 24 of 
treatment, at 6-week intervals from week 24 to 
week 48 of treatment, and at 12-week intervals 
thereafter. All visits included evaluations of vital 
signs, adverse events, and concomitant medica-
tions. Tumor response and progression were 
evaluated by means of computed tomography, 
laboratory testing, and physical examination at 
screening and at weeks 8, 16, 24, 36, and 48 and 
every 12 weeks thereafter. Responses and dis-
ease progression were rigorously evaluated for 
each patient by an independent review commit-
tee that consisted of three board-certified radi-
ologists (two readers and one adjudicator) and 
one board-certified oncologist–hematologist.
Statistical Analysis
The study used Simon’s two-stage design28 and 
with a sample of at least 100 patients had a pow-
er of more than 90% to test the hypothesis that 
the response rate would be 39% or higher against 
the null hypothesis that it would be 20% or lower, 
at a one-sided significance level of 0.005. Response 
rates, exact binomial 95% confidence intervals, 
and P values (based on the exact binomial test) 
were calculated. Secondary end points of the du-
ration of response and progression-free survival 
were summarized with the use of the Kaplan–
Meier method. The date of progression was the 
date on which progression was first identified 
objectively. Death occurring within 30 days after 
discontinuation of the study drug was considered 
to be an event in the calculations of response and 
progression-free survival. Data from patients 
with nonprogressing disease were censored on 
the date of the last tumor assessment.
R esult s
Patient Characteristics
Between April 2011 and October 2012, we en-
rolled 125 patients with relapsed indolent non-
Hodgkin’s lymphoma. The date of data cutoff 
was June 25, 2013. Table 1 summarizes the base-
line characteristics of the patients. The median 
age of the patients was 64 years; 64% were male, 
and 89% were white. Most of the patients (89%) 
had stage III or IV indolent non-Hodgkin’s lym-
phoma, 30% had elevated lactate dehydrogenase 
levels, 26% had lesions that were 7 cm or more in 
at least one dimension, 15% had a hemoglobin 
level of less than 10 g per deciliter, 14% had a 
neutrophil count of less than 1500 per cubic mil-
limeter, and 8% had a platelet count of less than 
75,000 per cubic millimeter. Of the patients with 
follicular lymphoma, 79% had scores on the fol-
licular lymphoma International Prognostic Index 
that indicated intermediate risk or high risk, and 
17% had grade 3a disease (follicular large-cleaved-
cell lymphoma).
Patients had received a median of 4 prior regi-
mens (range, 2 to 12), with 73 patients (58%) hav-
ing received 4 or more prior regimens. Among 
alkylating agents, cyclophosphamide had been 
administered to 111 patients (89%) and benda-
mustine to 81 patients (65%). The most common 
prior regimens included bendamustine–rituximab 
(60 patients [48%]), rituximab–cyclophospha-
mide–doxorubicin–prednisone (R-CHOP) (56 pa-
tients [45%]), rituximab monotherapy (50 patients 
[40%]), and rituximab–cyclophosphamide–pred-
nisone (R-CVP) (36 patients [29%]). Fourteen pa-
tients (11%) had received prior high-dose chemo-
therapy and had undergone autologous stem-cell 
transplantation.
All the patients had disease that was refrac-
tory (as defined above) to rituximab, and 124 
patients (99%) had disease that was refractory to 
an alkylating agent; in 108 patients (86%), the 
disease was refractory to combination therapy 
with an alkylating agent and rituximab. A total 
of 99 patients (79%) had disease that was refrac-
tory to two or more prior regimens. Among pa-
tients who had received prior regimens consist-
ing of bendamustine plus rituximab, R-CHOP, or 
R-CVP, 78%, 71%, and 81%, respectively, had dis-
ease that was refractory to those therapies. A to-
tal of 112 patients (90%) had disease that was 
refractory to the last therapy they had received 
immediately before idelalisib.
Efficacy
A waterfall plot of the best overall response with 
respect to tumor size shows that 110 of 122 pa-
tients who could be evaluated (90%) had a reduc-
tion in the size of lymph nodes during treatment 
(Fig. 1). On the basis of assessment by the inde-
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pendent review committee, the response rate was 
57% (95% confidence interval, 48 to 66), with 71 
responses in 125 patients. A total of 7 patients 
(6%) had a complete response, 63 patients (50%) 
had a partial response, and 1 patient (1%) with 
Waldenström’s macroglobulinemia had a minor 
response. There was a high degree of concordance 
between the assessments of response by the in-
dependent review committee and the assess-
ments by the investigators, with 85% agreement 
with respect to overall response (Table S1 in the 
Supplementary Appendix, available at NEJM.org). 
The rates of response were consistent across sub-
groups, with favorable response rates observed 
regardless of the number of prior regimens, re-
fractoriness of the disease to the most recent 
prior therapy, refractoriness to bendamustine, dis-
ease subtype, bulky disease status, age, and sex 
(Fig. 2). The response rates ranged from 47 to 
80% in various subgroups. There was no correla-
tion of efficacy with pharmacokinetic measures 
(Fig. S2 in the Supplementary Appendix).
Responses were rapid and durable with con-
tinued administration of idelalisib. The median 
time to a response was 1.9 months (range, 1.6 to 
8.3) (Fig. 3A). The median duration of response 
was 12.5 months (range, 0.03 to 14.8) (Fig. 3B), 
exceeding the median duration of response (5.9 
months) in the group of 28 patients who had 
had a response to the most recent therapy before 
idelalisib. The median progression-free survival 
was 11.0 months (range, 0.03 to 16.6) (Fig. 3C), 
with 47% of the patients remaining progression-
free at 48 weeks. At the time of data cutoff, the 
median overall survival was 20.3 months (range, 
0.7 to 22.0) (Fig. 3D), and overall survival at 1 year 
was estimated to be 80%. The median follow-up 
time was 9.7 months.
Safety Profile
The median duration of treatment with idelalisib 
was 6.6 months (range, 0.6 to 23.9), and the mean 
(±SD) duration was 8.1±5.7 months. At the time 
of the data cutoff, 108 patients (86%) had received 
idelalisib at a dose of 150 mg twice daily for at 
least 2 months, and 68 patients (54%) had re-
ceived the drug for at least 6 months; treatment 
was ongoing for 40 patients (32%). The incidence 
rates of adverse events occurring during treatment 
in 10% or more of the patients are listed in Table 
2. The following events (all grades) occurred in 
more than 20% of patients: diarrhea (in 43%), 
fatigue (in 30%), nausea (in 30%), cough (in 29%), 



















































Figure 1. Best Overall Response.
The best response with respect to tumor size during idelalisib treatment, according to assessment by an indepen-
dent review committee, is shown for the 125 patients in the study. Among the 122 patients with measurable lesions 
both at baseline and after baseline, 110 patients (90%) had improvements in lymphadenopathy, as assessed by 
changes in the sums of the products of the perpendicular dimensions (SPD) of index lesions. The dashed line shows 
the percentage change that represents the criterion for lymphadenopathy response, according to Cheson et al.25 
FL denotes follicular lymphoma, LPL/WM lymphoplasmacytic lymphoma with or without Waldenström’s macro-
globulinemia, MZL marginal-zone lymphoma, and SLL small lymphocytic lymphoma.
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ported adverse events of grade 3 or higher were 
diarrhea (in 13% of the patients), pneumonia (in 
7%), and dyspnea (in 3%). The most common 
laboratory abnormalities of grade 3 or higher 
that occurred during treatment (Table 2) includ-
ed neutropenia (in 27% of the patients) and ele-
vations in levels of serum alanine or aspartate 
aminotransferase (in 13%). Other cytopenias of 
grade 3 or higher included thrombocytopenia (in 
6% of the patients) and anemia (in 2%). Changes 
in blood counts during therapy are described in 
Table S1 in the Supplementary Appendix. There 
were no significant changes in immunoglobulin 
levels or T-lymphocyte subsets.
Adverse events led to discontinuation of idel-
alisib in 25 patients. These adverse events in-
cluded elevations in levels of serum alanine or 
aspartate aminotransferase in 5 patients (4%), 
colitis in 4 patients (3%), pneumonia and pneu-
monitis in 3 patients each (2%), and diarrhea and 
neutropenia in 2 patients each (2%). The initial 
dose of 150 mg twice daily was reduced to 100 mg 
twice daily or to 75 mg twice daily in 42 patients 
(34%). The adverse events that led most fre-
quently to dose reduction were elevations in 
levels of serum alanine or aspartate aminotrans-
ferase, followed by diarrhea and neutropenia. The 
most common serious adverse events included 
pyrexia in 13 patients (10%), pneumonia and di-
arrhea in 9 patients each (7%), colitis in 5 pa-
tients (4%), dehydration and febrile neutropenia 
in 4 patients each (3%), and acute renal failure 
and pneumonitis in 3 patients each (2%).
Grade 3 or higher diarrhea, colitis, or both 
developed in 20 patients (16%), at a median of 
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Figure 2. Forest Plot of Overall Response Rate.
A forest plot is shown of the overall response rate, in the total cohort and according to subgroups, among patients 
with refractory indolent non-Hodgkin’s lymphoma. The response rate was assessed by an independent review com-
mittee. The dashed line shows the null hypothesis response rate of 20%. LD denotes longest diameter.
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1 to 13); of these, 6 cases resolved spontaneously 
or after dose reduction, 6 cases (2 in patients 
with progressive disease) led to permanent dis-
continuation of idelalisib, and 8 cases resolved 
with a temporary interruption of the drug. Of 
the 8 patients in whom the drug was temporar-
ily interrupted, 5 were able to resume therapy 
without a recurrence of toxic effects.
In all patients with grade 1 or 2 elevations in 
levels of serum alanine or aspartate aminotrans-
ferase, the levels returned to values within normal 
ranges despite the fact that the patients contin-
ued taking the drug. Grade 3 or higher elevations 
of serum aminotransferase levels developed in 
16 patients (13%), at a median of 6.3 weeks after 
the initiation of treatment (range, 4 to 11). These 
cases were asymptomatic and after interruption 
of idelalisib therapy, all resolved to grade 1 or less 
within a median of 3.9 weeks (range, 1 to 6). 
Fourteen patients were rechallenged, 10 of whom 
(71%) were successfully able to continue therapy 
with a temporary dose reduction and subsequent 
reescalation.
A total of 28 deaths (22%) were reported. 
Eleven deaths occurred while the patient was re-
ceiving the study drug or within 30 days after 
the last dose. The causes of death were progres-
sive disease (3 patients), pneumonia (3 patients), 
and cardiac arrest, cardiac failure, splenic infarc-
tion, septic shock, and pneumonitis (1 patient 
each). The remaining 17 deaths, due predomi-
nantly to progressive disease, occurred during 
long-term follow-up. No evidence of cumulative 
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Figure 3. Kaplan–Meier Curves for Secondary End Points.
Kaplan–Meier curves are shown for the secondary end points of the time to response (Panel A), the duration of response (Panel B), pro-
gression-free survival (Panel C), and overall survival (Panel D) among patients with refractory indolent non-Hodgkin’s lymphoma who 
were treated with idelalisib (intention-to-treat population). The end points were assessed by an independent review committee. 
The New England Journal of Medicine 
Downloaded from nejm.org at WASHINGTON UNIV SCH MED MEDICAL LIB on April 9, 2014. For personal use only. No other uses without permission. 
 Copyright © 2014 Massachusetts Medical Society. All rights reserved. 
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
n engl j med 370;11 nejm.org march 13, 20141016
Discussion
In this noncomparative trial, idelalisib showed 
antitumor activity in patients with indolent non-
Hodgkin’s lymphoma that had become refractory 
to both rituximab and alkylating agents. Idela-
lisib monotherapy resulted in tumor reductions in 
90% of the patients, with 57% meeting the crite-
ria for an objective tumor response. Disease con-
trol could be protracted: the median duration of 
response was 12.5 months, and the median pro-
gression-free survival was 11.0 months. Objective 
responses were observed in patients with follicu-
lar lymphoma and small lymphocytic lymphoma, 
as well as in patients with the rarer subsets of 
indolent non-Hodgkin’s lymphoma — marginal-
zone lymphoma and lymphoplasmacytic lympho-
ma with or without Waldenström’s macroglobu-
linemia. Thus, therapeutic targeting of the PI3Kδ 
pathway may be clinically relevant in all these 
B-cell cancers.
The value of this regimen included a favorable 
toxicity profile, with low rates of discontinuation 
due to toxic effects and a low incidence of severe 
adverse events. Though serum elevations in he-
patic aminotransferase levels were observed in 
47% of patients, elevations of grade 3 or higher 
occurred in 13% of patients, were reversible in 
all patients, and resulted in discontinuation of 
treatment in only 5 patients (4%). Grade 3 or 
higher diarrhea or colitis occurred in 13% and 4% 
of the patients, respectively, and could often be 
managed with interruptions in drug treatment or 
adjustments of the dose.
Clinically significant hematologic toxic effects 
were also uncommon. Since we designed the trial 
for a patient population that had received exten-
sive prior treatment, we specifically allowed the 
use of red-cell and platelet transfusions as well 
as neutrophil growth factors to meet the protocol-
required baseline eligibility thresholds for pa-
tients with impaired marrow reserve or extensive 
tumor infiltration. In this context, the 27% rate 
of neutropenia of grade 3 or higher was not con-
sidered to be excessive, and febrile neutropenia 
was a rare event, occurring in 4 patients (3%).
The results with idelalisib are similar to 
those observed in evaluations of other cytotoxic 
and noncytotoxic agents in previously treated 
patients. 131I-tositumomab and 90Y-ibritumomab, 
when studied in rituximab-refractory follicular 
lymphoma, yielded response rates of 62 to 74% and 
progression-free survival of 6.8 to 8.8 months.29,30 
The alkylating agent bendamustine was approved 
for the treatment of indolent non-Hodgkin’s lym-
phoma that is refractory to rituximab, on the 
basis of a response rate of 75% and a median 
duration of response of 9.2 months in a cohort 
of patients who had received a median of two 
Table 2. Adverse Events during Treatment.*
Event or Abnormality Grade
Any ≥3
no. (%)
Adverse event 103 (82) 68 (54)
Diarrhea 54 (43) 16 (13)
Nausea 37 (30) 2 (2)
Fatigue 37 (30) 2 (2)
Cough 36 (29) 0
Pyrexia 35 (28) 2 (2)
Decreased appetite 22 (18) 1 (1)
Dyspnea 22 (18) 4 (3)
Abdominal pain 20 (16) 3 (2)
Vomiting 19 (15) 3 (2)
Upper respiratory tract infection 18 (14) 0
Weight decreased 17 (14) 0
Rash 16 (13) 2 (2)
Asthenia 14 (11) 3 (2)
Night sweats 14 (11) 0
Pneumonia 14 (11) 9 (7)
Peripheral edema 13 (10) 3 (2)
Headache 13 (10) 1 (1)
Hematopoietic laboratory abnormality
Decreased neutrophils 70 (56) 34 (27)
Decreased hemoglobin 35 (28) 2 (2)
Decreased platelets 32 (26) 8 (6)
Chemical laboratory abnormality
Increased ALT 59 (47) 16 (13)
Increased AST 44 (35) 10 (8)
Increased alkaline phosphatase 28 (22) 0
Increased bilirubin 13 (10) 0
* Included are adverse events and selected laboratory abnormalities that oc-
curred during treatment in 10% or more of the 125 patients in the study, 
 regardless of whether the event was related to the study drug. Adverse events 
that occurred during treatment are classified according to the preferred term 
in the Medical Dictionary for Regulatory Activities (MedDRA), version 15.1. 
Patients who had multiple events within the same preferred-term category 
were counted once in that category. ALT denotes alanine aminotransferase, 
and AST aspartate aminotransferase.
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prior regimens.31 A 30-patient subgroup from 
the bendamustine trial,31 comprising patients with 
alkylator-refractory disease, had a response rate 
of 64% and median progression-free survival of 
7.5 months. The majority of patients treated with 
idelalisib in the current trial had received prior 
therapy with bendamustine. Other noncytotoxic 
agents, such as bortezomib,32 fostamatinib,33 
ibrutinib,34 and lenalidomide,35 have been asso-
ciated with response rates of 12 to 52% in popu-
lations that received less extensive prior therapy 
than did those taking idelalisib in this study.
In conclusion, in this uncontrolled trial, idel-
a lisib targets the PI3Kδ pathway and appears to 
provide effective oral monotherapy in patients 
with previously treated indolent non-Hodgkin’s 
lymphoma. The toxicity profile does not gener-
ally overlap with that of most other active agents 
and may allow the development of more highly 
active combination regimens.
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